EE159 Cost Effectiveness of Pembrolizumab Combined with Chemotherapy Vs. Chemotherapy As First-Line Treatment for Metastatic TNBC That Expresses PD-L1 in the United States

Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.408
https://www.valueinhealthjournal.com/article/S1098-3015(22)00609-X/fulltext
Title : EE159 Cost Effectiveness of Pembrolizumab Combined with Chemotherapy Vs. Chemotherapy As First-Line Treatment for Metastatic TNBC That Expresses PD-L1 in the United States
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00609-X&doi=10.1016/j.jval.2022.04.408
First page :
Section Title :
Open access? : No
Section Order : 10358
Categories :
Tags :
Regions :
ViH Article Tags :